Enhancement of Corticosteroid Efficacy in COPD

NCT ID: NCT02340520

Last Updated: 2018-06-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-12-31
• Study Completion Date: 2016-08-31

Brief Summary

This is a pilot study designed to evaluate the effects of theophylline and roflumilast on circulating Histone deacetylase (HDAC) levels in subjects with COPD, and the bronchodilator effects of corticosteroids. Studies will be performed in 10 subjects with COPD nonresponsive to bronchodilators. Subjects will receive theophylline tablets for 1 week, followed by measurement of circulating HDAC and the acute effect of oral prednisone on the bronchodilator response to inhaled beta agonist. Roflumilast tablets will be added to the theophylline for a further week and the studies repeated. The study will provide preliminary data on the effects of theophylline and roflumilast on circulating HDAC levels and the effects of corticosteroids on the beta agonist bronchodilator response in COPD.

Detailed Description

1. SUBJECTS: 10 Stable patients >45 years of age, with an established diagnosis of COPD (18), with FEV1 <60% predicted, FEV1/FVC <70% and <+15% FEV1 response to bronchodilator will be recruited. Patients of both genders will be included.

2. TESTS

a) Blood: i) HDAC 2 in peripheral blood mononuclear cells: ii) Serum theophylline level b) Spirometry for measurement of FVC, FEV1 and FEV1/FVC

PROCEDURES Visit 1.

1. After providing informed consent, subjects will receive a brief history and physical examination

2. Blood will be drawn from a peripheral vein for HDAC2 levels (2 ml).

3. Each subject will undergo baseline spirometry, which will be repeated after 3 inhalations of an albuterol inhaler.

c) Subjects will be asked to continue their regular treatment regimen, including long and short acting beta agonists and anticholinergics, as well as inhaled steroids.

d) Theophylline tablets extended-release 12 hr formulation, 300 mg orally taken every 12 hr will be dispensed, and the subject will return one week later for Visit 2. The subject will be asked to refrain from using his/her long acting beta agonists and anticholinergics for one day (24 hours) prior to Visit 2, and not to use the short acting beta agonist or take any caffeine containing drinks on the morning of visit 2. The subject will be asked to inform the P. I. should there be any adverse event.

Subjects discontinuing the study drugs because of side effects will be withdrawn from the study.

Visit 2.

1. A brief history and physical examination will be performed and the subject will be asked about any change in symptoms.

2. Blood (5 ml) will be drawn from a peripheral vein for HDAC2 and theophylline levels

3. After baseline spirometry the subject will be given a single dose of 40 mg prednisone tablets.

4. After 120 minutes, spirometry will be repeated, followed by 3 puffs of albuterol inhaler and repeat spirometry.

The subject will then be asked to continue the theophylline tablets and in addition will be given roflumilast tablets 500 mcg orally once daily, and asked to return one week later for Visit 3.

The subject will be asked to refrain from using his/her long acting beta agonists and anticholinergics for one day (24 hours) prior to Visit 3, and not to use the short acting beta agonist or take any caffeine containing drinks on the morning of visit 3. The subject will be asked to inform the P. I. should there be any adverse event.

Visit 3

1. A brief history and physical examination will be performed and the subject will be asked about any change in symptoms.

2. Blood (5 ml) will be drawn from a peripheral vein for HDAC2 measurement.

3. After baseline spirometry the subject will be given a single dose of prednisone tablets in a dose of 40 mg.

4. After 120 minutes, spirometry will be repeated, followed by 3 puffs of albuterol inhaler and repeat spirometry.

The subject will then have completed the study and will return to his/her previous treatment regimen.

Data analysis:

Results will be compared in terms of baseline vs drug by paired t test for change in FEV1 and FEV1/FVC as well as peripheral blood mononuclear blood HDAC2 levels. The relationship between FEV1 and FEV1/FVC and blood HDAC2 levels will be examined by correlation analysis.

Expected results It is expected that with both theophylline and roflumilast treatment there will be a significant (p<0.05) increase in HDAC2 levels. It is also expected that with both theophylline and roflumilast treatment there will be a significant (p<0.05) increase in the bronchodilator response after the steroid dose, thereby supporting the hypothesis.

It is also possible that there will be no effect on spirometry of either treatment; this would indicate that an increase in HDAC2 does not improve steroid responsiveness.

Conditions

COPD

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

thophylline and roflumilast

Theophylline for one week, followed by the addition of Roflumilast for a further one week.

Group Type: EXPERIMENTAL

Theophylline

Intervention Type: DRUG

Oral

Roflumilast

Intervention Type: DRUG

Oral

Interventions

Theophylline

Oral

Intervention Type: DRUG

Roflumilast

Oral

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Established diagnosis of COPD with FEV1 <60% predicted
• FEV1/FVC <70% and <+15% FEV1 response to bronchodilator.
• Patients of both genders will be included.
• IRB approved written informed consent will be obtained from each subject.

Exclusion Criteria

1. Recent (<1 month) exacerbation of COPD,

2. Known hypersensitivity to beta agonists, theophylline, steroids, or roflumilast.

3. Current or recent (<2 weeks) treatment with oral steroids, theophylline or other methylxanthines, or roflumlast.

4. Diagnosis or history of asthma, uncontrolled hypertension, or congestive heart failure.

5. History of Cardiac arrhythmia

6. History of seizures.

7. History of Liver disease

8. Gastrointestinal disease, including history of peptic ulcer disease.

9. Current infection or antibiotic treatment.

10. History of depression or psychiatric disease.

• Minimum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

UConn Health

OTHER

Sponsor Role: lead

Responsible Party

Nausherwan Burki

Professor of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Nausherwan Burki

Role: PRINCIPAL_INVESTIGATOR

UConn Health

Locations

UConnHealth

Farmington, Connecticut, United States

Countries

United States

Other Identifiers

14-032-3

Identifier Type: -

Identifier Source: org_study_id